Replies to post #180658 on Biotech Values

[justrpaul]

Gilead CC -

They estimated that 70% of Sovaldi sales were for Olysio/Sovaldi combinations.

[rajaram46]

Dew,

What do you think of GILD's valuation now? I know you wanted to buy in the low 60's. Are you still concerned about the HIV franchise?

Missed this one.....

[DewDiligence]

GILD -4% AH on “light” 3Q14 results:

http://blogs.barrons.com/stockstowatchtoday/2014/10/28/gilead-sciences-earnings-miss-forecasts-as-aca-drives-higher-costs/

Gilead reported a profit of $1.84 a share not including special items, missing forecasts for $1.92 a share, on sales of $6.04 billion, topping estimates for $5.98 billion. …Affordable Care Act-related costs knocked 21 cents off of earnings.

3Q14 Sovaldi sales were $2.80B (vs $3.84B in 2Q14), of which ~$2.2B was from the US market. (The Harvoni launch occurred after the end of 3Q14.)

GILD’s PR:
http://finance.yahoo.com/news/gilead-sciences-announces-third-quarter-200500161.html